Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Clin Infect Dis ; 78(2): 453-456, 2024 02 17.
Artículo en Inglés | MEDLINE | ID: mdl-37805935

RESUMEN

Chagas disease (CD), caused by Trypanosoma cruzi, is underdiagnosed in the United States. Improved screening strategies are needed, particularly for people at risk for life-threatening sequelae of CD, including people with human immunodeficiency virus (HIV, PWH). Here we report results of a CD screening strategy applied at a large HIV clinic serving an at-risk population.


Asunto(s)
Enfermedad de Chagas , Infecciones por VIH , Trypanosoma cruzi , Humanos , Estados Unidos/epidemiología , VIH , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/complicaciones , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Infecciones por VIH/complicaciones
2.
Nat Med ; 28(6): 1288-1296, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35551291

RESUMEN

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-center, randomized, double-blind, dose-escalation, placebo-controlled first-in-human trial of the HIV-1 V2-glycan-specific antibody PGDM1400 alone or in combination with the V3-glycan-specific antibody PGT121 in 24 adults without HIV in part 1, as well as a multi-center, open-label trial of the combination of PGDM1400, PGT121 and the CD4-binding-site antibody VRC07-523LS in five viremic adults living with HIV not on antiretroviral therapy (ART) in part 2 ( NCT03205917 ). The primary endpoints were safety, tolerability and pharmacokinetics for both parts and antiviral activity among viremic adults living with HIV and not on ART for part 2 of the study. The secondary endpoints were changes in CD4+ T cell counts and development of HIV-1 sequence variations associated with PGDM1400, PGT121 and VRC07-523LS resistance in part 2. Intravenously administered PGDM1400 was safe and well-tolerated at doses up to 30 mg kg-1 and when given in combination with PGT121 and VRC07-523LS. A single intravenous infusion of 20 mg kg-1 of each of the three antibodies reduced plasma HIV RNA levels in viremic individuals by a maximum mean of 2.04 log10 copies per ml; however, viral rebound occurred in all participants within a median of 20 days after nadir. Rebound viruses demonstrated partial to complete resistance to PGDM1400 and PGT121 in vitro, whereas susceptibility to VRC07-523LS was preserved. Viral rebound occurred despite mean VRC07-523LS serum concentrations of 93 µg ml-1. The trial met the pre-specified endpoints. Our data suggest that future bNAb combinations likely need to achieve broad antiviral activity, while also maintaining high serum concentrations, to mediate viral control.


Asunto(s)
Infecciones por VIH , Seropositividad para VIH , VIH-1 , Adulto , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Neutralizantes , Antivirales/uso terapéutico , Anticuerpos ampliamente neutralizantes , Anticuerpos Anti-VIH , Humanos , Viremia/tratamiento farmacológico
3.
Nat Med ; 27(10): 1718-1724, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34621054

RESUMEN

Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg-1 in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy (ART), as well as a multicenter, open-label trial of one infusion of PGT121 at 30 mg kg-1 in viremic HIV-infected adults not on ART (no. NCT02960581). The primary endpoints were safety and tolerability, pharmacokinetics (PK) and antiviral activity in viremic HIV-infected adults not on ART. The secondary endpoints were changes in anti-PGT121 antibody titers and CD4+ T-cell count, and development of HIV-1 sequence variations associated with PGT121 resistance. Among 48 participants enrolled, no treatment-related serious adverse events, potential immune-mediated diseases or Grade 3 or higher adverse events were reported. The most common reactions among PGT121 recipients were intravenous/injection site tenderness, pain and headache. Absolute and relative CD4+ T-cell counts did not change following PGT121 infusion in HIV-infected participants. Neutralizing anti-drug antibodies were not elicited. PGT121 reduced plasma HIV RNA levels by a median of 1.77 log in viremic participants, with a viral load nadir at a median of 8.5 days. Two individuals with low baseline viral loads experienced ART-free viral suppression for ≥168 days following antibody infusion, and rebound viruses in these individuals demonstrated full or partial PGT121 sensitivity. The trial met the prespecified endpoints. These data suggest that further investigation of the potential of antibody-based therapeutic strategies for long-term suppression of HIV is warranted, including in individuals off ART and with low viral load.


Asunto(s)
Antivirales/administración & dosificación , Anticuerpos ampliamente neutralizantes/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , Adulto , Terapia Antirretroviral Altamente Activa , Antivirales/inmunología , Antivirales/farmacocinética , Anticuerpos ampliamente neutralizantes/inmunología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/virología , Método Doble Ciego , Femenino , Proteína gp120 de Envoltorio del VIH/antagonistas & inhibidores , Proteína gp120 de Envoltorio del VIH/inmunología , Infecciones por VIH/genética , Infecciones por VIH/patología , Infecciones por VIH/virología , VIH-1/patogenicidad , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/inmunología , Placebos , Carga Viral/efectos de los fármacos , Carga Viral/inmunología , Adulto Joven
4.
Pathog Immun ; 5(1): 364-381, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33501400

RESUMEN

BACKGROUND: Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis. METHODS: Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured. RESULTS: Median age at week 0 was 39 years, CD4+ T cell count 496 cells/mm3, HIV RNA levels <20 copies/mL. FMT was safe and well-tolerated. α diversity increased in 4 participants from weeks 0 to 6, including the 3 with the lowest α diversity at week 0. At week 26, α diversity more closely resembled week 0 than week 6 in these 4 participants. Metagenomic analysis showed no consistent changes across all participants. One participant had high gut permeability and inflammation biomarker levels and low α diversity that improved between weeks 0 and 6 with a shift in distribution. CONCLUSIONS: Weekly FMT was safe and well-tolerated. α diversity increased in participants with the lowest baseline α diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.ClinicalTrials.gov Identifier: NCT03329560.

5.
Rev. med. Rosario ; 84(1): 11-16, ene.-abr. 2018. tab, ilus
Artículo en Español | LILACS | ID: biblio-973328

RESUMEN

Introducción: La infección por VIH puede asociarse a EPOC, sobre todo en estadios avanzados de enfermedad. La inflamación asociada al virus puede facilitar las alteraciones de la función respiratoria. Objetivos: Investigar la presencia de alteraciones de la función respiratoria en pacientes VIH positivos sin inmunocompromisoni hábito tabáquico. Comparar la función respiratoria de pacientes VIH con la población general(grupo control). Establecer la relación entre función pulmonar, sexo, edad del paciente, valor de CD4, uso de TARV,presencia de síntomas, enfermedad respiratoria y antecedentes de las mismas.Material y Métodos: Se realizó un estudio prospectivo, transversal, de tipo observacional y descriptivo. Luego deun análisis de la historia clínica y una entrevista en búsqueda de síntomas respiratorios, se estudiaron 68 pacientes,no fumadores, a los que se les realizó una espirometría. 46 (67%) eran VIH positivos (casos) y 22 (32,4%) VIH negativos (controles)...


Introduction: HIV infection can be associated with COPD, especially in advanced stages. Objectives: To investigate the presence of respiratory function alterations in HIV-positive patients without immunocompromiseor tobacco habit. Compare the respiratory function of HIV patients with the general population (control group).To establish the relationship between lung function and sex, age of the patient, CD4 value, use of ART, presence of symptoms, respiratory disease and history of symptoms. Material and Methods: A prospective, cross-sectional, observational and descriptive study was conducted. After a medical history analysis and an interview in search of respiratory symptoms, 68 patients, non-smokers, were studied and spirometry was performed. 46 (67%) were HIV positive (cases) and 22 (32.4%) were HIV negative (controls)...


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Infecciones por VIH/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA